[摘 要]目的 探讨外用1%西替利嗪滴剂治疗男性雄激素性秃发的临床效果及安全性。方法 选择2022年9月-2023年8月在济南市皮肤病防治院就诊的64例男性雄激素性秃发患者为研究对象，根据随机数字表法分成对照组与观察组，每组32例。对照组外用5%米诺地尔搽剂，观察组外用1%盐酸西替利嗪滴剂，比较两组临床疗效、毛发总密度、视觉主观评分及不良反应发生情况。结果 观察组治疗后总有效率为81.25%，略低于对照组的90.63%，但差异无统计学意义(P>0.05)；两组开始用药3、6个月后毛发总密度均高于开始用药前，但观察组开始用药3、6个月后毛发总密度低于对照组(P<0.05)；两组开始用药3个月后视觉主观评分比较，差异无统计学意义(P>0.05)；观察组开始用药6个月后视觉主观评分低于对照组(P<0.05)；两组用药后均未出现明显、严重不良反应。结论 1%西替利嗪滴剂治疗男性雄激素性秃发的效果肯定，可提高毛发总密度，改善头皮毛发视觉效果，是治疗AGA的一种新选择，且具有良好的安全性。

    [关键词] 雄激素性秃发；西替利嗪；米诺地尔

    [中图分类号] R758.71 [文献标识码] A [文章编号] 1004-4949(2024)12-0035-04

    Clinical Effect of 1% Cetirizine Hydrochloride Drops for External Use in the Treatment of Male Androgenetic Alopecia

    RUAN Zhen-qiang， JING Ming， LIU Ming， WANG Da-jian， YU De-bao

    (Jinan City Hospital for Skin Disease Prevention and Treatment， Jinan 250021， Shandong， China)

    [Abstract]Objective To investigate the clinical efficacy and safety of 1% cetirizine hydrochloride drops in the treatment of male androgenetic alopecia. Methods A total of 64 male patients with androgenetic alopecia who were treated in Jinan City Hospital for Skin Disease Prevention and Treatment from September 2022 to August 2023 were selected as the research objects. According to the random number table method ......